121 related articles for article (PubMed ID: 12361901)
1. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas.
Monier F; Mollier S; Guillot M; Rambeaud JJ; Morel F; Zaoui P
Eur Urol; 2002 Oct; 42(4):356-63. PubMed ID: 12361901
[TBL] [Abstract][Full Text] [Related]
2. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Yoshida O
J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
[TBL] [Abstract][Full Text] [Related]
3. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
6. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
[TBL] [Abstract][Full Text] [Related]
7. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
9. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J
Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191
[TBL] [Abstract][Full Text] [Related]
11. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis.
Sanders JS; Huitema MG; Hanemaaijer R; van Goor H; Kallenberg CG; Stegeman CA
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1927-34. PubMed ID: 17898039
[TBL] [Abstract][Full Text] [Related]
12. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
13. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Urology; 2001 Apr; 57(4):675-9. PubMed ID: 11306379
[TBL] [Abstract][Full Text] [Related]
14. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
15. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
16. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
[TBL] [Abstract][Full Text] [Related]
17. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
[TBL] [Abstract][Full Text] [Related]
18. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
[TBL] [Abstract][Full Text] [Related]
20. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]